AgeX Therapeutics

AgeX Therapeutics Overview

  • Founded
  • 2017
Founded
  • Status
  • Public
  • Employees
  • 17
Employees
  • Stock Symbol
  • AGE
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $0.90
  • (As of Tuesday Closing)

AgeX Therapeutics General Information

Description

AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develop innovative medicines designed to address some of the unsolved problems in aging. Its PureStem derived cell-based therapeutic candidates in development are AGEX-VASC1 and AGEX-BAT1. And iTR drug-based therapeutic candidates in development are AGEX-iTR1547 and Renelon.

Contact Information

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
ASE
Primary Office
  • 1010 Atlantic Avenue
  • Suite 102
  • Alameda, CA 94501
  • United States
+1 (510) 000-0000

AgeX Therapeutics Timeline

201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AgeX Therapeutics Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.90 $0.88 $0.67 - $3.36 $33.9M 37.7M 384K -$0.33

AgeX Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 35,017 66,107 107,042
Revenue 1,855 1,728 1,396 1,404
EBITDA (11,116) (11,314) (7,312) (5,943)
Net Income (12,208) (12,154) (7,502) (6,580)
Total Assets 5,092 7,442 10,671 9,631
Total Debt 2,092 1,956 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AgeX Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AgeX Therapeutics‘s full profile, request access.

Request a free trial

AgeX Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Michael West Ph.D Chief Executive Officer & Board Member
Ivan Labat Ph.D Chief Information Officer
Hal Sternberg Ph.D Vice President
Dana Larocca Ph.D Vice President, Discovery Research
Aubrey de Grey Ph.D Vice President of New Technology Discovery

1 Former Executive

AgeX Therapeutics Board Members (6)

To view AgeX Therapeutics‘s full board member team, request access »
Name Representing Role Since
Alfred Kingsley JD Self Chairman 000 0000
Annalisa Jenkins Self Board Member 000 0000
Gregory Bailey MD Self Chairman & Board Member 000 0000
Michael West Ph.D AgeX Therapeutics Chief Executive Officer & Board Member 000 0000

2 Former Board Members

AgeX Therapeutics Investments (1)

To view AgeX Therapeutics‘s complete investment and acquisition history, request access »
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 00000000000 16-Aug-2019 000000000 00000 00 Buildings and Property 0000000 0000 00.0

AgeX Therapeutics Subsidiaries (1)

Company Name Industry Location Founded
0000000 00000000 Alameda, CA